The expression of DOK5 was significantly reduced in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), head and neck cancer (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC), compared to adjacent normal tissues. Here, DOK5 is linked to head and neck cancer.